BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2000

View Archived Issues

Corixa subscribes to Incyte's LifeSeq Gold database

Read More

Telomerase gene therapy may offer potential liver cirrhosis therapy

Read More

Myriad Genetics advances drug discovery programs during second quarter

Read More

Anti-tat gene therapy blocks HIV replication, may offer new treatment alternative

Read More

Altus receives funding for GI lipase enzyme therapy

Read More

YM-872 exerts neuroprotective effects in rat transient MCA occlusion model

Read More

Human Genome Sciences moves three drugs into clinical development in 1999

Read More

SkyePharma achieves positive phase II results for DepoMorphine; DepoCyt approved in Canada

Read More

GenVec licenses gene for treating blindness

Read More

New study contradicts earlier indications of efficacy for ERT in treating Alzheimer's disease

Read More

Elan/Endorex joint venture to develop iron-chelating products with Schein

Read More

Modified oligonucleotides with staggered PS/PO linkages designed at Isis

Read More

CAN-296 may inhibit fungal ATPase-mediated proton pumping

Read More

Synaptic discovers potent and selective human alpha1D-adrenoceptor antagonists

Read More

Study disproves earlier reports of serious treatment-related side effect of deferiprone

Read More

NPY Y1-selective compounds for diagnostic, therapeutic use available for licensing

Read More

Compounds activating PPAR isoforms described by Merck for lipid disorders, diabetes

Read More

Salk team identifies potential target for the elusive male contraceptive

Read More

Orally active antiplatelet agents in development at Lafon

Read More

Merck presents new nonpeptide GnRH antagonists

Read More

Immune Response's mbGM-CSF vaccine offers protection against melanoma

Read More

Pregabalin now claimed for renal colic-associated pain

Read More

Ono claims selective EP4 receptor ligands and their use

Read More

New treatment for COPD from Ono to enter clinical trials soon

Read More

AMPA antagonists improve neurological outcome in EAE

Read More

Nastech's NDA for intranasal scopolamine not accepted for filing

Read More

Remicade recommended for approval in E.U. for treatment of rheumatoid arthritis

Read More

FDA issues approvable letter for Pharmacia & Upjohn's Vestra

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing